Portfolio
2
companies
Syndex Bio
Syndex Bio advances next-generation molecular diagnostics with its proprietary methyl-copying PCR platform.
Lightcast Discovery
Lightcast Discovery builds a novel single-cell functional analysis platform for life science research.
ARCH Venture Partners led the oversubscribed round alongside participation from +ND Capital, OMX Ventures, and Meltwind.
"Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring."
M Ventures led the Series B round to support the company ahead of its commercial launch.
"The power of single-cell analysis to uncover the complexities of biology has become increasingly evident, but much of the work still focuses on the transcriptome as the primary readout."
